Enliven Therapeutics (NASDAQ:ELVN) Stock: Insider Benjamin Hohl Sells 6,018 Shares

Posted by Brenda Bartman on Oct 23rd, 2026

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the sale, the chief financial officer owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $50.35, for a total transaction of $303,006.30.
On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $58.58, for a total transaction of $352,534.44.

Enliven Therapeutics Stock Up 0.3%

NASDAQ:ELVN opened at $41.93 on Friday. The firm’s 50 day moving average is $50.61 and its two-hundred day moving average is $48.02. Enliven Therapeutics, Inc. has a fifty-two week low of $14.78 and a fifty-two week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.79 EPS for the current year.

More Enliven Therapeutics News

Here are the key news stories impacting Enliven Therapeutics this week:

Positive Sentiment: HC Wainwright issued fiscal 2026 and 2027 EPS estimates while maintaining its Buy rating and $73 target. The firm expects a 2026 loss of $1.74 per share, slightly better than the $1.81 consensus forecast, providing a favorable valuation signal if Enliven meets expectations. HC Wainwright estimates and analyst coverage
Positive Sentiment: The broader analyst view remains supportive: Enliven has a reported “Moderate Buy” consensus, with an average price target of approximately $75.44. Institutional ownership is also high at about 95%, and several major funds recently initiated or expanded positions.
Neutral Sentiment: HC Wainwright’s quarterly forecasts indicate continued losses, including EPS estimates of negative $0.41 in Q3 2026, negative $0.46 in Q4 2026, and negative $0.48 to negative $0.55 across the first four quarters of 2027. The estimates offer forward visibility but confirm that the clinical-stage biotechnology company is not yet profitable.
Negative Sentiment: CFO Benjamin Hohl sold 6,018 shares for $231,572.64, reducing his direct ownership by 13.67%. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which reduces its significance as a discretionary bearish signal, but repeated sales could still weigh on investor sentiment. He retains 38,000 shares. CFO stock sale article
Negative Sentiment: Enliven previously reported a quarterly loss of $0.49 per share, worse than the $0.39 consensus estimate. Continued operating losses and the need for future clinical success remain key risks for ELVN investors.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the business. KBC Group NV purchased a new stake in Enliven Therapeutics during the 1st quarter worth $38,000. Sterling Capital Management LLC increased its holdings in Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after purchasing an additional 1,771 shares in the last quarter. State of Wyoming acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at $96,000. FNY Investment Advisers LLC acquired a new stake in Enliven Therapeutics in the 2nd quarter valued at $126,000. Finally, Royal Bank of Canada raised its position in Enliven Therapeutics by 345.0% in the first quarter. Royal Bank of Canada now owns 5,424 shares of the company’s stock valued at $212,000 after purchasing an additional 4,205 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research reports. William Blair started coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating for the company. HC Wainwright raised their price objective on Enliven Therapeutics from $65.00 to $73.00 and gave the stock a “buy” rating in a report on Monday. Stifel Nicolaus lifted their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim reaffirmed a “buy” rating on shares of Enliven Therapeutics in a research note on Thursday, October 8th. Finally, Mizuho boosted their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Check Out Our Latest Stock Analysis on ELVN

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.